Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1060-1067
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1060
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1060
Mean age at diagnosis (yr) | 12.62 (0.8-64) SD ± 13.42 | Diffuse astrocytoma grade II | 4/30 (13.3%) |
Gender | Anaplastic astrocytoma | 10/30 (33.3%) | |
Male | 31 (63.3%) | Glioblastoma multiforme | 4/30 (13.3%) |
Female | 18 (36.7%) | Astroblastoma | 1/30 (3.3%) |
According to age | Nonspecified glioma | 5/30 (16.7%) | |
Children and adolescents | 40 (81.6%) | No | 19 (38.8%) |
Adults | 9 (18.4%) | Radiological diagnosis | |
Duration of symptoms (d) | 83.4, SD ± 47.5 | Focal | 12 (24.5%) |
Karnofsky Performance Status | 80 (50-100) | Tectal | 3 (6.1%) |
Symptoms at time of presentation | Dorsally exophytic | 6 (12.2%) | |
Headache | 21 (42.8%) | Cervicomedullary | 3 (6.1%) |
Vomiting | 11 (22.4%) | DIPG | 22 (44.9%) |
Diplopia/ squint | 19 (38.8%) | Others | 3 (6.1%) |
Unsteady gait | 17 (34.7%) | Surgery | 30/49 (61.2%) |
Difficulty in swallowing or choking | 13 (26.5%) | Total/maximal resection | 14/30 (36.7%) |
Motor weakness/ paresis | 10 (20.4%) | Subtotal resection | 14/30 (36.7%) |
Convulsions | 4 (8.2%) | Biopsy only | 2/30 (6.1%) |
Dysphonia/ dysarthria | 11 (22.4%) | VP shunt | 19/30 (63.3%) |
Altered consciousness | 5 (10.2%) | ETV | 4/30 (13.3%) |
Isolated facial paresis | 6 (12.2%) | EDV | 5/30 (16.7%) |
Hearing problems | 3 (6.1%) | IONP | 14/30 (36.7%) |
Fever | 2 (4.1%) | Radiation therapy | 32/49 (65.3%) |
Failure to thrive | 1 (2.0%) | Postoperative | 14/32 (43.7%) |
Neurological signs at time of presentation | Radiotherapy alone | 18/32 (56.3%) | |
Mental status change | 8 (16.3%) | Total dose (Gy) | 50.4-59.4 |
Cranial nerve palsies | 32 (65.3%) | Fractions | 30-33 |
Trigeminal | 2 (6.3%) | Duration (wk) | 6-6.5 |
Abducens | 18 (56.3%) | Technique | |
Facial | 12 (37.5%) | 3DCRT | 15 (46.9%) |
Vestibulocochlear | 2 (6.3%) | IMRT | 17 (53.1%) |
Glossopharyngeal | 12 (37.5%) | Chemotherapy | 23/49 (46.9%) |
Vagus | 8 (25.0%) | Concurrent | 12/23 (52.2%) |
Motor deficit | 14 (28.6%) | TMZ | 12/12 (100%) |
Sensory deficit | 6 (12.2%) | Neoadjuvant | 7/23 (30.4%) |
Bilateral Babinski sign | 13 (26.5%) | Vincristine + carboplatin | 4/7 (51.1%) |
Cerebellar signs | 25 (51.0%) | High dose chemotherapy with stem cell rescue | 2/7 (28.7%) |
Nystagmus | 17 (34.7%) | Cyclophosphamide | 1/7 (14.3%) |
Bilateral papilledema | 19 (38.8%) | Adjuvant/ salvage | 11/23 (47.8%) |
Pathological diagnosis | BCNU + procarbazine + vincristine | 5/11(45.7%) | |
Yes | 30 (61.2%) | Vincristine + carboplatin | 4/11 (36.2%) |
Pilocytic astrocytoma | 6/30 (20.0%) | Irinotecan + bevacizumab | 2/11 (18.1%) |
- Citation: Bayoumi Y, Sabbagh AJ, Mohamed R, ElShokhaiby UM, Maklad AM, Tunio MA, Balbaid AAO. Clinicopathological features and treatment outcomes of brain stem gliomas in Saudi population. World J Clin Oncol 2014; 5(5): 1060-1067
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/1060.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.1060